PharmaEssentia Corp (藥華醫藥) yesterday said that phase-three European clinical trials for its bone marrow disease treatment may be completed three months earlier than expected, as its European partner is likely to register a sufficient number of subjects soon.
PharmaEssentia chairman Jan Ching-leou (詹青柳) said AOP Orphan Pharmaceuticals AG may be able to recruit 256 people with polycythemia vera in Europe by the end of next quarter, rather than by the end of this year as it projected earlier.
As a result, the two companies are expected to launch its P1101 (AOP2014) protein drug in Europe by the end of 2016, instead of 2017, Jan said.
Last month, the Taiwanese firm filed an investigational new drug (IND) application with US authorities, said Ellen Chang (張慧敏), a financial department director at PharmaEssentia.
It might take about a month for the US Food and Drug Administration (FDA) to decide whether the company can use the European clinical trial data for its permit application in the US, she added.
If the US FDA approves PharmaEssentia’s proposal, the company expects to launch the drug in the US at the same time as in Europe, Chang said.
Based on the company’s estimates, it will take three to five years for sales of the drug to reach peak sales, which are expected to be about US$1 billion a year in the US, and the same in Europe.
There are about 149,000 people in the US with polycythemia vera, a blood disorder in which the bone marrow makes too many red blood cells. In Europe, about 100,000 people have the disease.
The company said P1101 is more potent and has fewer side effects than the existing Jakafi treatment, launched by US-based Incyte Corp last year.
PharmaEssentia said it plans to price P1101 lower than Jakafi, which costs patients US$120,240 a year, to gain market share.
Meanwhile, PharmaEssentia on Monday applied to the Ministry of Economic Affairs to be recognized as a technology enterprise, so it can shift its stock listing to the GRETAI Securities Market next year.
In related news, drugmaker Medigen Biotechnology Corp (基亞生技) yesterday said that it is able to start the interim analysis of its data for phase three clinical trials of PI-88 treatment for liver cancer in Taiwan, China, Hong Kong and South Korea.
The company is to review the data on July 27 and disclose the results immediately after the reviewing meeting.
If the analysis yields positive results, Medigen expects to acquire a drug permit in Taiwan by the end of this year.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts